Baicalein Ameliorates Streptococcus suis-Induced Infection In Vitro and In Vivo

Hao Lu,Xiaodan Li,Gaoyan Wang,Chenchen Wang,Jiajia Feng,Wenjia Lu,Xiangru Wang,Huanchun Chen,Manli Liu,Chen Tan
DOI: https://doi.org/10.3390/ijms22115829
IF: 5.6
2021-05-29
International Journal of Molecular Sciences
Abstract:As an important zoonotic pathogen, Streptococcus suis (S. suis) infection has been reported to be a causative agent for variety of diseases in humans and animals, especially Streptococcal toxic shock-like syndrome (STSLS), which is commonly seen in cases of severe S. suis infection. STSLS is often accompanied by excessive production of inflammatory cytokines, which is the main cause of death. This calls for development of new strategies to avert the damage caused by STSLS. In this study, we found for the first time that Baicalein, combined with ampicillin, effectively improved severe S. suis infection. Further experiments demonstrated that baicalein significantly inhibited the hemolytic activity of SLY by directly binding to SLY and destroying its secondary structure. Cell-based assays revealed that Baicalein did not exert toxic effects and conferred protection in S. suis-infected cells. Interestingly, compared with ampicillin alone, Baicalein combined with ampicillin resulted in a higher survival rate in mice severely infected with S. suis. At the same time, we found that baicalein can be combined with meropenem against MRSA. In conclusion, these results indicate that baicalein has a good application prospect.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?